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Composite outcomes seem an attractive method to increase statistical power, but they can mask
the effect of treatment
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According to international guidelines,1 2 outcome measures in
a clinical trial should address the risks and benefits of a
treatment, be relevant to patients, and be sufficiently common
to make the trial feasible. In an attempt to meet these objectives
many investigators select outcomes such as all cause mortality,
all hospital admissions, or any adverse event. These outcomes
can be thought of as composite outcomes as they combine
multiple outcomes that are cause specific. All cause mortality
is a popular outcome measure because it is believed to provide
the net effect of the treatment, it seems more patient relevant
than cause specific mortality, and it provides more outcomes
so should increase statistical power. Another common approach
to increase power is to use wide case definitions and sensitive
tests.
In recent years several papers have reviewed and debated the
use of composite outcomes in clinical trials.3-9 Authors agree
on their advantages and disadvantages, and a good summary
can be found in a recent report from the European Network for
Health Technology Assessment.10 Briefly, the main objection
to the use of composite outcomes is that, if the treatment has
different effects on the different components of the outcome,
the net effect on the composite outcome is difficult to interpret.
It also complicates patient management decisions, raising the
question of which particular component outcome is more
relevant for each patient.
However, in the ongoing debate little emphasis has been given
to the fact that, by including events that are not causally related
to the treatment (either by using a composite outcome or by
misclassifying events with a wide case definition), the overall
effect of the trial will be diluted towards the null. In this paper
we explain why dilution occurs, provide examples of trials
where this has happened, and discuss how dilution can offset
many of the supposed advantages.
Motivating example: planning a clinical
trial
Having reviewed the existing evidence, you believe that β
blockers might improve lung function and so reduce hospital
admissions in patients with chronic obstructive pulmonary
disease (COPD), although you are worried that theymight cause
severe bronchospasm in some patients. You decide to conduct
a randomised controlled trial comparing β blockers with placebo
in people with moderate COPD. Because of the large burden
on health services and the importance for the patients, you define
the primary outcome as the risk of hospital admission over one
year. Your practice records show that patients with moderate
COPD have a 40% risk of being admitted to hospital each year
(although only half of admissions are for COPD). The statistician
says that a study of about 1510 patients followed up for a year
should have enough power to detect a 20% decrease in
admissions (that is, from 40% to 32%). Because of your concern
about bronchospasm, participants are asked to keep a diary of
episodes of wheeze or shortness of breath as well as more severe
symptoms. Severe bronchospasm is rare in people with COPD
(about one episode per 10 person years), although many feel
wheezy or short of breath (about once a week).
Imagine that trial recruitment went well and that table 1⇓ shows
the (hypothetical) results. There is no significant reduction in
hospital admissions and no evidence of increase in the adverse
event. Should you conclude that β blockers have no beneficial
or adverse effects?
This example has been made up to show how real treatment
effects can be diluted by using non-specific outcome measures.
Patients are admitted to hospital for many different reasons.
“Any hospital admission” can be considered a composite of
different cause specific admissions. In this example, half of
admissions were related to COPD. If we examine only COPD
related admissions there is some evidence of a treatment effect.
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We see the same thing with adverse events. Even though β
blockers did increase the risk of severe bronchospasm, the ability
of the trial to detect this effect is lost altogether because the
outcome measure includes wheeze and shortness of breath,
which are common in COPD patients and are not affected by
the intervention. If outcomes that are causally related to the trial
treatment are combined with those that are not, the estimate of
the treatment effect is diluted towards the null and we may fail
to identify potentially important benefits or harms.
Explaining treatment effects with a causal
mechanism model
The effect of a treatment on a health outcome can be shown
using the causal mechanism model described by Rothman and
colleagues.11 For a patient to experience a specific health
outcome, a particular set of events, conditions, or characteristics
must occur. This set is called the causal mechanism. The causal
mechanism is considered sufficient to produce the health
outcome, and each component cause is necessary in the sense
that had it been absent, that outcome would not have occurred.
The same health outcome might result from different causal
mechanisms sharing some component causes, and different
outcomes might arise from similar causal mechanisms. A trial
treatment has the potential to cause a change in health outcome
by blocking (or adding) one or more of the necessary component
causes in the causal mechanism. We would say that a health
outcome is causally related to a treatment if some causal
mechanisms contain component causes that are blocked by the
treatment. Figure 1⇓ shows a hypothetical trial with three
outcomes: red, blue, and green. For simplicity, we assume that
the same number of patients was allocated to the treated and
untreated groups, so that the relative risk is the ratio of patient
outcomes. Treatment can prevent some (but not all) of the red
outcome. In this example, the red outcome is causally related
to the treatment whereas the blue and green outcomes are not.
Composite outcomes
A composite outcome combines different outcomes (with
different causal mechanisms).1 The effect of a treatment on a
composite outcome is a weighted average of its effects on the
outcomes that are combined. In fig 1 the treatment halves the
occurrence of the red outcome (relative risk =0.5) but has no
effect on the blue outcome (relative risk=1.0). The relative risk
of the outcome red or blue is the weighted average of the relative
risks for the red and blue outcomes: relative risk red or
blue=0.5(10/13)+1.0(3/13). Where (10/13) and (3/13) are the
relative weights of the red and the blue outcomes in the untreated
group. If a composite includes outcomes that are not causally
related to the treatment, the relative risk for the composite is
diluted towards the null.12 Because few treatments will be
causally related to all causes of death, all cause mortality is a
composite outcome that combines causally related causes of
death with those unrelated to the treatment.
Misclassification of outcome
Many trials use diagnostic tests to assess the presence or absence
of a health outcome. For example, troponin levels might be used
to determine the presence or absence of a myocardial
infarction.13 Whatever method is used to assess outcome, there
will be false positives and false negative results. The number
of false positives divided by the total number of positive
outcomes is the proportion of false positives. Figure 2⇓ shows
the effect of outcome misclassification on the relative risk in a
trial. Each arm is assumed to have 2000 participants and each
circle represents 20 outcomes. The treatment effect estimated
using the causally related outcome is 100/200 (relative risk=0.50,
95% confidence interval 0.40 to 0.63). Some related outcomes
have low biomarker values and some unrelated outcomes have
high biomarker values. The misclassification of outcomes, the
proportion of false positives, and the relative risk will change
depending on the biomarker’s cut-off value. If we define the
outcome as present when the biomarker value is more than
seven, we will miss 20 causally related outcomes in the
treatment group and 40 in the untreated group. We also add 20
false positive outcomes to both groups. Because false positive
outcomes are included, the relative risk moves closer to the null
(relative risk=0.56, 0.44 to 0.70). The dilution is greater if we
define the outcome as present when the biomarker value is more
than three, because there are even more false positive results
(0.62, 0.51 to 0.74). Rodgers and McMahon14 showed that,
whatever the true relative risk, the estimated relative risk moves
towards the null as the proportion of false positive results
increases.
Figure 2⇓ also shows that as the number of outcomes increases,
the precision of the relative risk increases (narrower confidence
interval). However, in this case we are more certain about the
answer to a different question. With the biomarker cut-off at 3,
we have a precise estimate (0.62, 0.51 to 0.74) but one that
excludes the true relative risk of 0.5. Notice that, on the other
hand, the higher the value required in the biomarker, the more
real outcomes that we will fail to detect (false negative results).
The increase in false negative results will reduce the power of
the analysis but will not cause dilution as this is only caused by
the inclusion of false positives.
Examples from real trials
The CRASH-2 trial is a randomised placebo controlled trial of
tranexamic acid versus placebo in bleeding trauma patients.15
The primary outcomewas “all-cause mortality in hospital within
4 weeks of injury.” However, tranexamic acid was expected to
work by reducing bleeding in which case death from bleeding
is arguably the causally related outcome. The relative risk for
death from bleeding with tranexamic acid was 0.85 whereas the
relative risk for non-bleeding deaths was 0.94. In the untreated
group, 36% of deaths were due to bleeding and 64% to other
causes. The relative risk on all cause mortality was the weighted
average of the two effects: relative risk=0.91=0.85×0.36 +
0.94×0.64 (fig 3(a)⇓).
The Heart Protection Study is a randomised controlled trial of
simvastatin versus placebo in 20 500 patients at high risk of
cardiovascular events.16 The aim was to evaluate effects of
cholesterol lowering on patient outcomes. There were concerns
about a possible increase in the risk of myopathy, defined as
“unexplained muscle pains or weakness” (myalgia) with raised
levels of the enzyme creatine kinase. Reports of myalgia were
collected from trial participants and creatine kinase was
measured in these patients. Figure 3(b) shows the effect of
simvastatin on myalgia for different cut-off values of creatine
kinase. As the cut- off value is reduced there are more myalgia
outcomes and so the confidence interval is narrower. However,
the relative risk moves closer to the null. Myalgia is a common
symptom and is likely to havemany different mechanisms.Most
cases will not be causally related to the treatment. Nevertheless,
the possibility that some cases might be related to treatment
cannot be excluded from these data.
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Discussion
Composite outcomes are often used to obtain more outcome
events and thus increase statistical power.17 This is reasonable
if all components of the composite are causally relevant and the
treatment effects are similar. If the treatment effects vary
considerably between outcome components the trial provides
a more precise answer but to an irrelevant average effect that
does not represent any meaningful clinical effect. Furthermore,
if some components are not causally related to the treatment,
the effect of treatment will be diluted towards the null, offsetting
the gain in precision and not increasing the power of the trial
(as shown in the examples above). The real solution may be to
increase the sample size until there is enough power to answer
the question for the outcome of interest.
The CONSORT guideline recommends that the main outcome
should be something “relevant to the patient.”2 It is tempting to
assume that composites such as all cause mortality, any hospital
admission, overall quality of life, or any adverse event, might
be more relevant to patients than a particular cause of death or
a particular adverse effect. However, such composite outcomes
may not provide the information needed for patient care. In
practice, each patient has a different risk profile for each of the
components of the composite. Even if all cause mortality is the
outcome that matters to patients, knowing how the treatment
affects specific causes of death is more important for patient
management.
It is also tempting to believe that all cause mortality provides
the net effect of the treatment17 and so provides an attractive
summary for policy makers. However, conclusions made on the
basis of the effect on a composite outcome are applicable to the
population where the trial took place and are not readily
generalisable to other populations.10 The net effect on a
composite outcome in a given population depends on the relative
frequency of the component outcomes. Even if the effects on
specific component outcomes are the same across populations,
the net effect on the composite will not be the same if the
distribution of component outcomes varies. In particular, the
net effect of the composite outcome will be diluted in
populations where the components that are not causally related
to the treatment were common. In a multisite or multinational
trial, the net effect might vary by hospital or country even if the
specific effects remain constant.
In clinical practice, doctors often prefer highly sensitive
diagnostic tests that have a low proportion of false negative
results to ensure that few patients are denied an effective
treatment. However, in clinical trials, it is important to use
highly specific diagnostic tests that have a low proportion of
false positive results to prevent dilution of the treatment effect.
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Summary points
The use of non-specific or composite outcomes could increase the proportion of events that are not causally related to the intervention
Including events that are not causally related to the intervention will dilute the estimated effect towards the null and can result in more
precise estimates of the wrong effect and a reduction of the power in the trial
Effects on composite outcomes may not provide the information needed for individual patient care
Conclusions made on the basis of the effect on a composite outcome are not readily generalisable to other populations
Table
Table 1| Results for an example trial of β blockers in chronic obstructive pulmonary disease (COPD)
P valueRelative risk/rate† (95% CI)
Control (n=775)*β blocker (n=775)*
Outcome Risk/rate†No of patients/eventsRisk/rate†No of patients/events
Hospital admission
<0.120.90 (0.79 to 1.02)0.43020.35272Any cause
<0.0450.80 (0.65 to 0.99)0.21510.16121COPD related
Adverse events
<0.291.01 (0.99 to 1.02)0.143139 4440.144239 746Any shortness of breath
<0.00014.96 (3.91 to 6.40)0.0003760.0014378Severe bronchospasm
*275 575 patient days of follow-up.
†Hospital admissions are described as risks and adverse events as rates.
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Figures
Fig 1 Example of composite outcome, only one part of which (red outcome) is related to treatment. We assume the same
number of patients in each arm of the trial. (RR= relative risk, R=red, B=blue, and G=green)
Fig 2 Example of misclassification of outcomes in a randomised controlled trial based on biomarker level, 20 patients per
circle and assuming a total of 2000 patients randomised to each arm. The effect of treatment on aetiologically related
outcomes (red circles) is relative risk=0.5. (RR= relative risk, B=biomarker, PFP=proportion of false positive results)
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Fig 3 Examples of composite outcomes diluting effects of treatment from (a) the CRASH-2 trial15 and (b) the Heart Protection
Study16 (CK=creatine kinase, ULN=upper limit of normal)
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